peptide-based delivery technology

Feldan Therapeutics is a clinical-stage biotech company specializing in the development of treatments based on the intracellular delivery of therapeutics. It has developed the Feldan Shuttle®, a proprietary peptide-based technology enabling safe, rapid, and efficient delivery of antisense oligonucleotides (ASO) to cells, giving access to intracellular targets otherwise beyond reach. The company is conducting a Phase 1 clinical trial of FLD-103 for basal cell carcinoma and advancing FLD-201, an inhaled therapy for mucus-driven respiratory diseases, in pre

Read more

clinical developmentintracellular delivery of antisense oligonucleotides (ASO)preclinical development